Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

SURVIVEiT® – Giving Week 2019

At SURVIVEiT, we believe that everyone deserves access to the very best in cancer care and we believe that everyone can be their best advocate, with a little help from...
insightful_breath

“What Was That Again?”

SURVIVEiT Advisory Chair, Peggy Pollock updated her blog with a new update on her latest lung cancer biopsy report and processing updates: What Was That Again? -Peggy Pollock Dennis, The Insightful...
FDA_Drug_Newsroom

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma On June 10, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck) for the first-line treatment...
FDA_Drug_Newsroom

FDA approves pembrolizumab for metastatic small cell lung cancer

FDA approves pembrolizumab for metastatic small cell lung cancer On June 17, 2019, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small...
FDA_Drug_Newsroom

FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant

FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant On June 27, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with...

Fearless Friday: Cancer Research – What it does for *ALL* patients.

Fearless Friday: Cancer Research - What it does for *ALL* patients. We're wrapping up National Cancer Research Month! Though it hasn't lead to a targeted therapy option for her, Peggy...
New_FDA_Approval!

FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma

FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) plus axitinib for the...
New_FDA_Approval!

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma On April 12, 2019, the Food and Drug Administration granted accelerated approval to erdafitinib (BALVERSA, Janssen Pharmaceutical Companies) for patients...
New_FDA_Approval!

FDA expands pembrolizumab indication for first-line treatment of NSCLC

FDA expands pembrolizumab indication for first-line treatment of NSCLC On April 11, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck Inc.) for the first-line treatment of patients with...
New_FDA_Approval!

FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma

On February 22, 2019, the Food and Drug Administration approved trifluridine/ tipiracil tablets (LONSURF, Taiho Pharmaceutical Co., Ltd.)—a fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine...
Screen_Shot_4

Relax Comorbidity Criteria in Cancer Trials?

Relax Comorbidity Criteria in Cancer Trials? More than 6,000 additional patients could be enrolled each year by Ian Ingram, Deputy Managing Editor, MedPage Today January 14, 2019 As efforts are being made to...
New_FDA_Approval!

FDA approves cabozantinib for hepatocellular carcinoma

FDA approves cabozantinib for hepatocellular carcinoma On January 14, 2019, the Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously...